These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 20579701

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Primary application study in early diagnosis of bladder cancer by survivin molecular beacons.
    Zhao J, He D, He H, Li L, Zhang LL, Wang XY.
    Urology; 2007 Jul; 70(1):60-4. PubMed ID: 17656209
    [Abstract] [Full Text] [Related]

  • 3. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
    Parekattil SJ, Fisher HA, Kogan BA.
    J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
    [Abstract] [Full Text] [Related]

  • 4. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 5. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
    Eissa S, Swellam M, Shehata H, El-Khouly IM, El-Zayat T, El-Ahmady O.
    J Urol; 2010 Feb; 183(2):493-8. PubMed ID: 20006858
    [Abstract] [Full Text] [Related]

  • 6. Voided urinary cytology in bladder cancer: is it time to review the indications?
    Talwar R, Sinha T, Karan SC, Doddamani D, Sandhu A, Sethi GS, Srivastava A, Narang V, Agarwal A, Adhlakha N.
    Urology; 2007 Aug; 70(2):267-71. PubMed ID: 17826487
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M, Hakenberg OW, Gunia S, Pohling P, Helke C, Lübbe L, Nowack R, Siegsmund M, Hoschke B.
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [Abstract] [Full Text] [Related]

  • 9. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
    Pu XY, Wang ZP, Chen YR, Wu YL, Wang HP, Wang XH.
    Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
    [Abstract] [Full Text] [Related]

  • 10. Detection of survivin expression in cervical cancer cells using molecular beacon imaging: new strategy for the diagnosis of cervical cancer.
    Xue Y, An R, Zhang D, Zhao J, Wang X, Yang L, He D.
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):204-8. PubMed ID: 21752529
    [Abstract] [Full Text] [Related]

  • 11. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.
    Degtyar P, Neulander E, Zirkin H, Yusim I, Douvdevani A, Mermershtain W, Kaneti J, Manor E.
    Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510
    [Abstract] [Full Text] [Related]

  • 12. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ.
    Arch Esp Urol; 2002 Feb; 55(1):41-9. PubMed ID: 11957750
    [Abstract] [Full Text] [Related]

  • 13. Accuracy of the ImmunoCyt assay in the diagnosis of transitional cell carcinoma of the urinary bladder.
    Feil G, Zumbrägel A, Päulgen-Nelde HJ, Hennenlotter J, Maurer S, Krause S, Bichler KH, Stenzl A.
    Anticancer Res; 2003 Feb; 23(2A):963-7. PubMed ID: 12820331
    [Abstract] [Full Text] [Related]

  • 14. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.
    Guo B, Luo C, Xun C, Xie J, Wu X, Pu J.
    Exp Oncol; 2009 Mar; 31(1):43-7. PubMed ID: 19300416
    [Abstract] [Full Text] [Related]

  • 15. A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot.
    Eissa S, Swellam M, Labib RA, El-Zayat T, El Ahmady O.
    J Urol; 2009 Mar; 181(3):1353-60. PubMed ID: 19185322
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer.
    Dalbagni G, Han W, Zhang ZF, Cordon-Cardo C, Saigo P, Fair WR, Herr H, Kim N, Moore MA.
    Clin Cancer Res; 1997 Sep; 3(9):1593-8. PubMed ID: 9815848
    [Abstract] [Full Text] [Related]

  • 17. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
    Bowles L, Bialkowska-Hobrzanska H, Bukala B, Nott L, Razvi H.
    Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
    [Abstract] [Full Text] [Related]

  • 18. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
    Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P, Bouchot O, Beurton D, Coulange C, Rambeaud JJ.
    J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
    [Abstract] [Full Text] [Related]

  • 19. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
    Karnwal A, Venegas R, Shuch B, Bassett J, Rajfer J, Reznichek R.
    Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
    [Abstract] [Full Text] [Related]

  • 20. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
    Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, Procop GW, Jones JS, Ulchaker J, Zippe CD, Tubbs RR.
    J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.